|
Contact Us
|
RFP
|
Media Center
|
Study Participants
|
Investigators
|
Français
Overview
History
Leadership Team
Executive Committee
Corporate Responsibility
Overview
Phase I-IIa
First-in-Man
Diverse Experience
Modern Facilities
Project Management
Rapid Recruitment
Proof-of-Concept
Bioavailability / Bioequivalence / Biosimilars
Drug Drug Interaction
QT/TQT Capabilities
Special Populations
Bioanalytical
Non-GLP Analysis
Method Development & Validation
Biomarkers
Large Molecule Analysis
Clinical Lab
Assay List
Instrumentation
Phase IIb-III
Biostatistics and Statistical Programming
Clinical Monitoring
Data Management
Feasibility Studies
Global Safety and Pharmacovigilance
Interactive Response Technologies
Investigator Recruitment and Site Management
Medical and Scientific Affairs
Medical Writing
Project Management
Patient Recruitment Services
Program Branding and Communications
Advertising and Promotion
Referral Network Management
Rater Training
Phase IV
Observational Research and Patient Registries
Interventional IIIB/IV Studies
Health Economics and Outcomes Research
Risk Management and Epidemiology
Quality Assurance
Consulting
505(b)(2)
Biostatistics
Business Plan Services
Chemistry, Manufacturing, and Controls (CMC)
Clinical and Product Development
Global Safety and Pharmacovigilance
Pharmacokinetics and Pharmacodynamics (PK/PD)
Regulatory Services
Functional Service Providers
Staffing
Therapeutic Overview
Clinical Development Expertise
Biosimilars
Generics
Pediatrics
Small Molecule Therapeutics
Therapeutic Indications
Cardiovascular
Infectious Diseases/Vaccines
Neuroscience
Oncology
Pain
Overview
Asia Pacific
Europe
Latin America
North America
Overview
Articles
Brochures
Case Studies
Fact Sheets
PharmaNet Publications
Posters
Presentations
Videos/Podcasts/Webinars
White Papers
Overview
FAQ
Job Opportunities
Training Programs
Flexible Staffing
Print
this page
Email to
a Friend
Overview
Press Releases
2011
2010
2009
Company Fact Sheet
Logos
History
Leadership Team
Executive Committee
Corporate Responsibility
Conferences & Events
Press Releases
3/6/2012
ASLAN Pharmaceuticals Selects PharmaNet/i3 as Strategic Partner For Oncology Development
PharmaNet/i3 announced today that ASLAN Pharmaceuticals has selected PharmaNet/i3 as a Strategic Partner supporting the development of their oncology portfolio in Asia, and conducting Phase I and Phase II clinical trials for two of ASLAN’s compounds.
1/30/2012
Stephan Henauer to Head i3 Pharma Resourcing in Central, Eastern and Northern Europe
PharmaNet/i3 announced today that it has appointed Stephan Henauer, M.D., as Executive Director, i3 Pharma Resourcing. In this role, Dr. Henauer will provide leadership for PharmaNet/i3’s Staffing Business in Central, Eastern and Northern Europe.
1/24/2012
PharmaNet/i3 Announces the Opening of the 6th Edition of the Survey on Observational Research
PharmaNet/i3 announces the opening of the 6th Edition of the Survey on Observational Research. The survey is designed to enhance the understanding of observational research among sponsors, regulators, policymakers, physicians and patients.
